合并|北大肿瘤医院团队治疗伴PVTT肝癌取得重大突破( 三 ) 北大|进展|研究|门静脉|患者

文章图片

参考文献
[1]Zhang ZM, Lai EC, Zhang C, et al. The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus[J]. Int J Surg, 2015,20:8-16.
[2]Nakazawa T, Hidaka H, Shibuya A, et al. Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis[J]. BMC Gastroenterol, 2014,14:84.
[3]Katagiri S, Yamamoto M. Multidisciplinary treatments for hepatocellular carcinoma with major portal vein tumor thrombus[J]. Surg Today, 2014,44(2):219-226.
[4]Kokudo N, Takemura N, Hasegawa K, et al. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update[J]. Hepatol Res, 2019,49(10):1109-1113.
[5]Xie DY, Ren ZG, Zhou J, et al. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights[J]. Hepatobiliary Surg Nutr, 2020,9(4):452-463.
[6]Ikeda M, Shimizu S, Sato T, et al. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial[J]. Ann Oncol, 2016,27(11):2090-2096.
[7]Kudo M, Ueshima K, Yokosuka O, et al. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2018,3(6):424-432.
【合并|北大肿瘤医院团队治疗伴PVTT肝癌取得重大突破】[8]He M, Li Q, Zou R, et al. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial[J]. JAMA Oncol, 2019,5(7):953-960.